全文获取类型
收费全文 | 141877篇 |
免费 | 49360篇 |
国内免费 | 2518篇 |
专业分类
耳鼻咽喉 | 2133篇 |
儿科学 | 5664篇 |
妇产科学 | 1835篇 |
基础医学 | 23321篇 |
口腔科学 | 6196篇 |
临床医学 | 20143篇 |
内科学 | 34056篇 |
皮肤病学 | 8597篇 |
神经病学 | 16748篇 |
特种医学 | 4698篇 |
外国民族医学 | 7篇 |
外科学 | 21086篇 |
综合类 | 8337篇 |
现状与发展 | 11篇 |
一般理论 | 54篇 |
预防医学 | 9238篇 |
眼科学 | 3340篇 |
药学 | 12296篇 |
34篇 | |
中国医学 | 3922篇 |
肿瘤学 | 12039篇 |
出版年
2024年 | 109篇 |
2023年 | 681篇 |
2022年 | 1127篇 |
2021年 | 3849篇 |
2020年 | 6760篇 |
2019年 | 12283篇 |
2018年 | 11855篇 |
2017年 | 13019篇 |
2016年 | 13721篇 |
2015年 | 14309篇 |
2014年 | 14913篇 |
2013年 | 15917篇 |
2012年 | 9475篇 |
2011年 | 9795篇 |
2010年 | 12596篇 |
2009年 | 8379篇 |
2008年 | 6201篇 |
2007年 | 5112篇 |
2006年 | 4865篇 |
2005年 | 4321篇 |
2004年 | 3695篇 |
2003年 | 3558篇 |
2002年 | 3250篇 |
2001年 | 2729篇 |
2000年 | 2365篇 |
1999年 | 1558篇 |
1998年 | 611篇 |
1997年 | 479篇 |
1996年 | 407篇 |
1995年 | 338篇 |
1994年 | 316篇 |
1993年 | 267篇 |
1992年 | 544篇 |
1991年 | 512篇 |
1990年 | 466篇 |
1989年 | 434篇 |
1988年 | 372篇 |
1987年 | 390篇 |
1986年 | 338篇 |
1985年 | 283篇 |
1984年 | 210篇 |
1983年 | 153篇 |
1982年 | 98篇 |
1981年 | 92篇 |
1980年 | 93篇 |
1979年 | 160篇 |
1978年 | 94篇 |
1977年 | 75篇 |
1976年 | 80篇 |
1975年 | 78篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
2.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
3.
4.
5.
目的:对中药保质期或有效期进行系统的调研,探讨中药饮片设定保质期或有效期的依据及其必要性,为提高中药饮片质量、保障临床用药安全提供技术支撑,为药品监管部门制定有关法规提供科学依据。方法:以国家知识基础设施数据库(CNKI)为数据来源,采用文献计量学研究方法,选用检索词为“中药材”并“有效期”“饮片”并“有效期”,“饮片”并“保质期”“中药材”并“保质期”“中药材”并“效期”和“饮片”并“效期”,利用CNKI平台工具以及Excel统计工具进行统计分析。结果:经数据库检索、筛选,获取中药材、饮片保质期或有效期或效期的相关有效文献共85篇,其中关于中药、饮片保质期的相关文献26篇,中药、饮片有效期或效期的相关文献59篇;在59篇关于中药有效期的文献中,74.58%的文献对于中药是否应该制定有效期、如何制定有效期等展开了讨论,25.42%的文献为中药有效期研究的实验性文献。结论:本文从中药材、饮片保质期与有效期的现状,质量评价指标,研究方法,饮片分类、保质期制定的必要性,及其存在的问题和建议等方面进行了梳理和归纳,为中药饮片保质期制定,提供了详实的文献依据。 相似文献
6.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
7.
Sung‐Hyun Hwang Myung‐Chul Kim Sumin Ji Yeseul Yang Yeji Jeong Yongbaek Kim 《Cancer science》2019,110(4):1256-1267
Metformin, a drug for type 2 diabetes mellitus, has shown therapeutic effects for various cancers. However, it had no beneficial effects on the survival rate of human malignant mesothelioma (HMM) patients. The present study was performed to elucidate the underlying mechanism of metformin resistance in HMM cells. Glucose‐starved HMM cells had enhanced resistance to metformin, demonstrated by decreased apoptosis and autophagy and increased cell survival. These cells showed abnormalities in mitochondria, such as decreased ATP synthesis, morphological elongation, altered mitochondrial permeability transition pore and hyperpolarization of mitochondrial membrane potential (MMP). Intriguingly, Mdr1 was significantly upregulated in mitochondria but not in cell membrane. The upregulated mitochondrial Mdr1 was reversed by treatment with carbonyl cyanide m‐chlorophenyl hydrazone, an MMP depolarization inducer. Furthermore, apoptosis and autophagy were increased in multidrug resistance protein 1 knockout HMM cells cultured under glucose starvation with metformin treatment. The data suggest that mitochondrial Mdr1 plays a critical role in the chemoresistance to metformin in HMM cells, which could be a potential target for improving its therapeutic efficacy. 相似文献
8.
9.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
10.